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The purpose of this study was to determine the fatty acids composition 
in breast tissue of women with increased risk of developing breast cancer, 
and if the fatty acid composition in both phospholipid (PL) and 
triacylglycerol (TAG) in blood, both plasma and red blood cells (RBC), 
correlated to the fatty acid composition in breast tissue in the same 
population. Fifty subjects from clinical patients in a study to develop an 
assessment of breast cancer risk based on epidemiologic and biologic risk 
variables enrolled in current study. Blood and tissue samples were taken 
and dietary history questionnaire, which including usual supplement intake 
were distributed when the subjects were enrolled. The blood and breast 
tissue samples were analyzed by gas-liquid chromatography and 
calculated by the weighed percentage of total areas compared with 
Supelco 37 mixture as a standard. The means of total n-3 polyunsaturated 
fatty acids (PUFA) of PL in plasma and RBCs for the subjects were 4.00 ± 
1.09% and 5.47 ± 1.50%, respectively, and in plasma TAG the mean was 
2.21 ± 1.34%. The means of total n-3 PUFA of PL and TAG in breast tissue 
were 0.36 ± 0.27% and 1.28 ± 0.44%, respectively. The means of total n-6 
PUFA of PL in plasma and RBCs for the subjects were 34.04 ± 3.22% and 
28.10 ± 3.45%, respectively, and in plasma TAG was 28.35 ± 3.97%. The 




and 17.53 ± 2.78%. A statistically significant correlation was found in the 
ratio of total and long chain n-3 (n-3 LCPUFA) to total n-6 PUFA in PL in 
blood and breast tissue, r=0.801 and 0.653 for total n-3 PUFA in RBC and 
plasma (p<0.01), and r=0.631 and 0.524 for n-3 LCPUFA in RBC and 
plasma (p<0.01), but no relationship between breast and blood fatty acids 
in TAG in individual or combined n-3 and n-6 PUFA was found between 
breast tissue and blood. The ratio of long chain n-3 PUFA to total n-6 PUFA 
in phospholipid in blood represents the same ratio in breast tissue and 
could be used as a marker of breast phospholipid n-3 to n-6 ratio though 
relative amount of n-3 and n-6 fatty acids are very different between red 
blood cells and breast phospholipids.  
The only link found previously between fatty acids in breast tissue and 
breast cancer is related to the n-3 to n-6 fatty acid ratio in TAG. We need to 
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The relationship between the n-3 long chain polyunsaturated fatty acid 
(LCPUFA) in lipid classes from fine needle aspirates of the breast and those 
in the same lipid classes obtained from plasma and red blood cells (RBC) 
have not been reported. We studied their relationships in women at high 
risk for breast cancer who were on their usual intake of n-3 LCPUFA. 
Fatty acids in the plasma and red blood cell phospholipids are the usual 
biomarkers of n-3 LCPUFA status. They reflect both immediate (plasma) 
and long term or usual (RBC) n-3 LCPUFA intake. This is a pilot study for a 
planned study in the future to provide n-3 LCPUFA as a dietary supplement 
to women at high risk for breast cancer to measure cytokines and monitor 
the effect upon cellular biomarkers of cancer risk. The purpose of this study 
is to determine if breast tissue triacylglycerols (TAG) and phospholipids (PL) 
n-3 LCPUFA and the ratio of n-3 to n-6 fatty acids in breast tissue relate to 
the usual biomarkers of n-3 and n-6 LCPUFA status when n-3 LCPUFA 
intake is in presumed equilibrium. 
Some investigators found the lipid profile in TAG found in breast 
adipose tissue could be used to predict breast cancer risk. However, no 
previous study has investigated the relationship between fatty acid 




Statement of Purpose 
    The purpose of this study was to determine the fatty acid composition 
in breast tissue in women with increased risk of breast cancer and the fatty 
acid composition in both PL and TAG in blood (both plasma and RBC). The 
ultimate aim of this study is to determine if blood fatty acids could predict 
fatty acids in breast tissue aspirates. 
Research Questions 
1. What are the PL and TAG fatty acid profiles in fine needle aspirates of 
breast tissue in women at high risk for breast cancer? 
2. Do tissue LCPUFA or a combination of n-3 and n-6 fatty acids in 
phospholipids and triglycerides of fine needle aspirates of breast tissue 
correlate with plasma and RBC LCPUFA or ratios of n-3 to n-6 fatty acids 













Review of Literature 
It is not known how closely n-3 long chain polyunsaturated fatty acid 
(LCPUFA) in lipid classes from fine needle aspirates of the breast compare 
to n-3 LCPUFA in the same lipid classes obtained from plasma and red 
blood cells (RBC) in women at high risk for breast cancer who are on their 
usual intake of n-3 LCPUFA. 
Breast Cancer 
    Breast cancer forms in tissues of the breast. It usually occurs in the 
ducts and lobules, which are tubes that carry milk to the nipple and glands 
that make milk. In rare cases, breast cancer can start in other areas of the 
breast. Although the incidence of breast cancer is 100 times as frequent 
among women as among men, the survival rates of breast cancer are 
equal in both sexes (1). 
    Breast cancer is the second most common type of cancer after lung 
cancer. It accounts for 10.4% of all cancer incidences in both sexes 
combined (2). It is the fifth most common cause of cancer death (3). In 
2009, there were approximately 192,370 new diagnoses of breast cancer in 
females and 1910 diagnoses in male. Deaths in the US for breast cancer 
were approximately 40,170 in females and 440 in males (1). 




Breast cancer is the most frequent cancer and the first cause of death 
by cancer among women worldwide. Over the course of lifetime, one in 
eight women will be diagnosed with breast cancer in the United States. The 
estimated prevalence of breast cancer between 1990 to 2006 and the 
death rate from breast cancer in the US from 1975 to 2006 was 1.07% and 
0.03%, respectively, in female of all ages and races (1). 
Risk Factors of Breast Cancer 
    The primary risk factors for breast cancer include age, gender, family 
history, personal history of breast abnormalities, genes, race, menstrual 
cycle, alcohol and tobacco use, childbirth, hormone replacement therapy 
(HRT), obesity, radiation, and high-fat diet (4). 
    The risk of developing breast cancer increases in women as they get 
older, with the majority of breast cancer cases found in women older than 
50 years of age (4). As noted earlier, women are about 100 times more 
likely to be diagnosed with breast cancer than men (1). 
    A woman’s risk of breast cancer is higher if she has one or more first 
degree relatives, e.g., mother, sister or daughter, who are diagnosed with 
breast cancer. The higher maternal age at first live birth is associated with 
higher risk of breast cancer, but this depends on the family history of breast 
cancer. For women with 0 or 1 affected relatives, risk increases with age at 




decreases with age at first live birth (5). 
    Women who experienced early onset of menses (before 12 years old) 
or who experienced late menopause (after 55 years old) have a slightly 
higher risk of developing breast cancer (4). Since breast cancer usually 
occurs in ducts and lobules, abnormalities in these regions of the breast 
are associated with an increased risk of developing the breast cancer. And 
diagnose of breast cancer on one breast will increase the risk of breast 
cancer on the other breast.  
    Genes are a risk factor for breast cancer. Defects in BRCA1 and 
BRCA2 make people more prone to developing breast cancer. Women with 
a defect in one of these genes have up to an 80% chance of developing 
breast cancer (4). Caucasian women have greater risk of developing breast 
cancer than African American women and other races, although African 
American women have a higher death rate in those who diagnosed with 
breast cancer (4). 
Environmental factors also contribute to risk of breast cancer. For 
example, women who consume more than 1 to 2 glasses of alcohol a day 
may increase the risk of getting breast cancer (4). Women who received 
HRT to reduce their symptoms of menopause may also have a higher risk 
for breast cancer (6, 7). Radiation exposure on chest area as a child or 




increases risk of breast cancer (4). Recently published research indicates 
that breast tissue density may relate to the risk of breast cancer as well (8). 
However, the evidence for these factors is not conclusive. More research is 
needed to validate these risk factors. 
Diet and Risk of Breast Cancer 
    International variations in breast cancer incidence rates and changes 
in the incidence among migrant populations suggest breast cancer risk is 
influenced by environmental factors could be amenable to interventions (2).  
    Diet is one of the environmental factors shown to influence the risk of 
breast cancer. Few studies have been focused on the cancer incidence in 
relation to usual diet intake. Diet is thought to be responsible for about 30% 
to 40% of all cancers. In Asians, lower cancer risk may be due to the 
frequent consumption of soy products (11). Findings suggest that physical 
activity, a healthy diet (particularly one low in fat and high in vegetables and 
fiber), and a healthy weight can reduce the risk of breast cancer (4). 
    Bosetti et al. (10) reviewed studies conducted in Italy during the early 
1990s. He found that some certain unsaturated fats, such as olive oil, 
reduce the risk of breast cancer, while saturated fat intake was directly 
related to some common neoplasms, which is a result of the abnormal 
proliferation of cells. As a result, major characteristics of the Mediterranean 




cereals, fruits, and vegetables, moderate consumption of dairy products, 
fish, wine and low consumption of meat and meat products, may decrease 
the cancer risk. 
    Thomson et al. (11) suggested there is a possible benefit of a 
vegetable-rich, low-fat eating pattern on breast cancer survival. Lower fat 
intake and higher vegetable and fiber intake may result as well in mild to 
modest weight loss among overweight and obese women. Weight loss is 
associated with higher survivability of breast cancer. 
    Sue et al. (12) found a modest positive association between higher 
energy intake diet pattern and risk of breast cancer. They found 21% higher 
risk among women in the highest quartile of energy intake than the lowest 
quartile. This association is largely independent of Body Mass Index (BMI) 
and physical activity. Animal studies also provided consistent evidence that 
energy restriction reduces breast cancer risk. 
Consumption of soy products has been associated with lower risk of 
breast cancer, but this is not conclusive (2). For example, a German study 
found no relationship between soy products and breast cancer risk (13), 
while two other studies from the UK found increased breast cancer risk for 
dietary isoflavone intake (14,15). Two studies based on Asian population 
reported a decreased breast cancer risk was associated with higher dietary 




effects of soy products on the risk of breast cancer. 
    In conclusion, few dietary effects have been determined in relation to 
the risk of breast cancer. Variables studied have not produced convincing 
evidence of risk or benefit. Additional research is needed to address the 
importance of diet effect on women at high risk of breast cancer and breast 
cancer patients. Factors that influence individual recurrence risk of breast 
cancer, are related to diet need to be examined and established in the 
future as well. 
Dietary Fat May Alter the Outcome of Breast Cancer 
    The evidence on the relationship between dietary fat and the risk of 
breast cancer is mixed. Results of animal studies are consistent by 
showing an increased risk of mammary gland cancer when fat intake is 
increased (18). Human studies are different because different types of fatty 
acids are present in different kinds of foods and oils that may influence the 
risk of breast cancer at different levels.  
    Several studies have shown an association between fatty acid intake 
and mammary gland tumor incidence (19-23). After dietary 
supplementation, several fatty acids, such as alpha-linoleic acid, are 
selectively incorporated into membrane phospholipids of tumor cells 
suggests these fatty acids might influence tumor growth through an effect 




benign and malignant proliferation of breast tissue in women is associated 
with higher plasma lipids levels, and it is closely related to the progression 
of breast cancer (24, 25).  
    Two studies examined the effect of total fat intake on breast cancer risk. 
One of these studies reported a high fat diet was significantly associated 
with an increased risk of breast cancer (11). The other study reported a 
modest increase in the incidence of breast cancer in women who had a 
higher level of saturated fat intake (26). None of the available cohort 
studies reported an association between risk of breast cancer and a high 
fat intake. 
    Although these studies are not conclusive evidence fat plays a role in 
the development of breast cancer, the results of previous studies indicate 
that the relationship between dietary fat intake and risk of breast cancer is 
worthy of further study. 
Biomarker in Breast Cancer 
    A biomarker is a biological status or substance found and measured in 
blood, other body fluids, or tissues. It could be used as an indicator of a 
biological state in the body. It could be objectively measured or evaluated 
as a sign of normal biological process, pathogenic processes, or 
pharmacologic responses to therapy. The most common biomarkers used 




biomarkers are considered diagnostic biomarkers. When a biomarker is a 
reliable indicator for the risk of the disease, individuals identified at high risk 
of the particular disease should be considered to change any behavior(s) 
related to the biomarker. 
    Specific biological markers used for a given cancer have not proven 
fruitful. Most of the single clinical markers have low accuracy. One marker 
that is used for diagnosis of breast cancer, CA15.3, has a sensitivity of 23% 
and specificity of 69%. (27) Instead of single biomarker, a combination of 
biomarkers may increase the accuracy of prediction. Multiple markers may 
be very useful in future diagnosis of cancer or cancer risk with higher 
accuracy. 
The fatty acid composition of breast tissue could be used as a 
biomarker of the exposure to different dietary fatty acids. Yet the individual 
fatty acid approach may not be appropriate; a combination of fatty acids 
may need to be estimated due to the interaction between fatty acids. The 
complex correlation system needs to be simplified to a smaller number of 
dimensions (28). A review from Bougnoux reports on the lipid profile 
(lipidome), a composite of fatty acids in breast tissue triacylglycerols (TAG) 
that appears to constitute a biomarker for the risk of breast cancer (29). 
    The analysis of lipids is complicated by their unique and diverse 




analytical method is available to examine the full lipidome of biological 
mixtures in a single experiment (27). Michels et al. (30) found that diet 
assessment methods and other potential factors, such as measurement 
error and variation of diet, contribute to the difficulty in examining the 
relationship between dietary fat intake and fat composition in the body. 
Therefore, a biomarker that could reflect the fatty acids composition in the 
breast tissue is desired; e.g. ratio of n-3 to n-6 long chain polyunsaturated 
fatty acid (LCPUFA), for conducting future studies such as the effects of n-3 
LCPUFA on the risk of breast cancer. 
    Chajes et al. (31) reported the fatty acid composition of breast tissue 
was highly correlated with subcutaneous adipose tissue, suggested that 
the fatty acid composition of breast may reflect the whole body stores of 
these fatty acids. The fatty acid composition of white adipose tissue best 
reflects past dietary fat intake. It is relevant to examine the breast cancer 
risk and fat intake relationships in relation to fatty acid composition (28). 
However, a blood based marker that could reflect the fatty acid profile in 
breast tissue would be useful as breast biopsies are time consuming, 
cannot be done frequently compared to blood sampling and may be painful 
or lead to bleeding or bruising. Fine needles aspirates of breast tissue are 
routinely obtained from women in our clinical population who are at high risk 




Body fluids such as blood are little more trouble to be obtained for 
analysis of lipid classes than breast tissue, and blood plasma and red blood 
cells (RBCs) are commonly used as a biomarker because they carry a 
large number of metabolites (27). King et al. (32) reported that a 
combination of fatty acids could reflect the consumption of total dietary fat 
with high sensitivity and specificity. A biological marker of total fat intake in 
blood related to breast tissue would be useful to reflect the changes of fatty 
acid composition response to total fat intake. 
    It is possible to examine the relationship between fatty acids in lipid 
classes of fine needle aspirates of the breast and plasma and RBC in 
women at high risk for breast cancer. A study comparing the fatty acid 
composition of phospholipid (PL) and TAG in plasma or RBC with breast 
cancer risk were inconclusive (33). Two studies currently have reported 
fatty acids in breast tissue but fatty acid would be expected to be evaluated 
by the all types included in the aspirate, neither study reported total, PL or 
TAG fatty acids in plasma or RBC, as proposed here (23, 34). 
N-3 LCPUFA 
    N-3 (omega-3) LCPUFA are a family of unsaturated fatty acids that 
have a final carbon-carbon double bond in the omega-3 position, between 
the third and fourth carbon from the methyl end of the fatty acid. Important 




acid (EPA), and docosahexaenoic acid (DHA).  
    N-3 fatty acids play an important role in cell membrane functions and 
regulating the body's metabolic processes. Some foods are a good source 
of omega-3 fatty acids, compounds have a weak estrogen effect and can 
help reduce the risk of breast cancers depending on estrogen. 
    Cold-water fish are a good dietary source for n-3 LCPUFA and a few 
vegetable oils such as flaxseed, walnut, and canola are also high in alpha 
linolenic acid. In addition to the marine products and oils from special 
vegetables, whole grains, legumes, nuts and green leafy vegetables are 
also good sources of n-3 PUFA. 
The conversion of n-3 PUFA to n-3 LCPUFA occurs competitively with 
n−6 PUFA to n-6 LCPUFA, which are derived from another essential fatty 
acid – linoleic acid. Synthesis of the n−3 LCPUFA from linolenic acid within 
the body is competitively slowed by the n−6 analogues. Many chronic 
diseases are related to an imbalance intake in the omega-6 and omega-3 
fatty acids (34). As a result, the ratio of n-3 LCPUFA to n-6 LCPUFA 
becomes important for human health (34).  
N-3 LCPUFA and Risk of Breast Cancer 
    Several studies reported possible anti-cancer effects of n−3 fatty acids, 
including for breast cancer (35). For breast cancer, neither long-chain nor 




Higher levels of DHA, the most abundant n-3 LCPUFA in erythrocyte 
membranes, was associated with a reduced risk of breast cancer (36). 
    Maillard et al. (34) found that ALA (18:3n3) was inversely related to the 
risk of breast cancer in a case-control study. They also found ALA inhibited 
tumor development and growth in an animal system of 
N-methylnitrosourea-induced mammary tumors, but this effect is only 
present in the absence of the antioxidant vitamin E. These results indicate 
n-3 LCPUFA may inhibit tumor growth are substrates of lipid peroxides, 
which lead to tumor cell death. 
Bougnoux et al. (37) measured and determined the response to 
anticancer agents for breast cancer in relation to n-3 LCPUFA. They found 
the storage level of DHA (22:6n3) in lipids of patients was high, the 
responsive of mammary tumors to induction chemotherapy was increased. 
They found DHA increased cell lipid peroxidation and generated oxidative 
stress, which is the mechanism of many anticancer drugs when presented 
in medium of cultured mammary tumor cell lines. The effect was lost when 
an antioxidant such as vitamin E was present.  
In one animal study, rat mammary tumors were sensitized to epirubicin, 
an anticancer drug, when fish oil and oxidants were provided in the diet of 
the rat. The investigators suggested that because lipoperoxidation inhibits 




providing DHA substrate to tumor cells to improve lipoperoxidation would 
lead to an increased drug efficacy (23). 
    However, study results based on n-3 LCPUFA and risk of breast 
cancer are not consistent. There are 2 case-control studies done in North 
American people that found no protective effect of n-3 LCPUFA on breast 
cancer (38, 39). In contrast, the other case-control study conducted in 
Finland found a higher DHA level in breast adipose tissue related to dietary 
intake was associated with a lower incidence of breast cancer (40). 
    The ratio of n-3 LCPUFA to n-6 LCPUFA has an important effect on 
risk of breast cancer. Maillard et al. (34) reported a strong association 
between ratios of 18:3n3 to 18:2n6 or n-3 LCPUFA to the total n-6 fatty 
acids and reduction in risk of breast cancer. This indicates the protection of 
n-3 LCPUFA on breast cancer could depend on the background levels of 
total n-6 PUFA (34). A decreased risk of breast cancer was found with an 
increased ratio of n-3 LCPUFA to total n-6 PUFA in a case control study 
conducted across 5 European countries (41). 
    As a result, future studies and precise identification on the role of n-3 
LCPUFA on breast cancer will be needed to allow them to be used as 








The purpose of this study was to determine if the composition of breast 
tissue LCPUFA in PL and TAG correlated with blood level LCPUFA, and if 
the composition of fatty acids in plasma and RBCs could be a validated 
biomarker for breast tissue fatty acids composition, which may used in 
interventions related to breast cancer. 
Sample 
This study used a sample of convenience. The subjects were clinical 
patients enrolled in a on going study to develop an assessment of breast 
cancer risk based on epidemiologic and biologic risk variables. As part of 
the protocol, blood and tissue samples were taken and dietary history 
questionnaire (DHQ) (including usual supplement intake) were distributed 
when the subjects were enrolled.  
Women at increased risk of breast cancer but without any breast 
carcinoma were recruited into the study. The increased risk of breast 
cancer was defined by any of the following: having a mutation in a cancer 
suppressor gene (BRCA1, BRCA2, p53, etc.); having a first degree 
relatives with breast cancer or two or more second degree relatives with 
breast cancer; and having had a prior biopsy diagnosed on other breast 




Inclusion criteria. Subjects enrolled had to meet the inclusion criteria: 
1) the subject should be between the ages of 30 and 55 years old; 2) the 
subject must be more than six months from ingestion of antihormonal 
therapy; 3) the subject must be more than 1 year from pregnancy, lactation 
or chemotherapy; 4) mammograms of the subject had to be read as not 
suspicious for breast cancer; 5) the subject had to be willing to donate 
blood and tissue samples and complete personal dietary and health history 
information. 
Exclusion criteria. Subjects were excluded if they met any of 
following: 1) metastatic malignancy to other organs; 2) on Coumadin or 
other anticoagulants; 3) bilateral breast implants or tram flap reconstruction; 
4) had radiation to both breasts; 5) mammogram or clinical breast exam 
suspicious for breast cancer and malignancy not ruled out, and 6) who 
were unable to give an informed consent. 
Recruitment 
Women who met the inclusion and exclusion criteria were asked to 
participate in the study at University of Kansas Medical Center (KUMC). 
Enrollment of subjects started on June 2009 and was completed in January 
2010. Consent was explained and signed for every enrolled woman. 
Fifty-two subjects were enrolled in the study and provided a blood and 





The subjects were recruited at KUMC, Westwood, Kansas, and the 
fatty acids were analyzed in Dr. Susan Carlson’s lab in Department of 
Dietetics and Nutrition at KUMC. 
Ethical Issues 
This study was a pilot study to determine if blood can be used as a 
biomarker similar to breast tissue for studies to determine n-3 LCPUFA 
status. Approval for this substudy was under a blanket informed consent 
obtained by Dr. Carol Fabian, M.D. and her colleagues. This study 
approved by Human Subjects Committee at KUMC (HSC# 4601). 
The dietary history record and clinical interview, such as interview 
schedules and questionnaire were part of Katherine Harvey’s thesis. Her 
work was used to determine who took n-3 LCPUFA supplements in this 
study. The fatty acids analyses from the present study were used by her to 
determine if there was a relationship of dietary intake to tissue fatty acids in 
either breast or plasma and RBC lipids, in women at high risk of breast 
cancer.  
Procedures 
Each subject signed the informed consent document when enrolled in 
the study. The DHQ was distributed and blood and breast tissue samples 




completed it. Katherine Harvey R.D. checked and analyzed the mailed 
back DHQ. 
Ten milliliters of venous blood was collected with into a tube containing 
K3-EDTA. Blood was not collected after fasting. Plasma and RBC were 
separated and store at -80°C until analysis. A number of aspirates of breast 
tissue (approximately 6-8/procedure) were also obtained and kept at -80°C. 
The aspirates were defined as real breast tissues with liquid around them in 
this study. Just prior to analysis, the aspirates of breast tissue were 
combined and a uniform aliquot taken for the PL and TAG analysis 
(Appendix A).  
Total lipids were extracted from all specimens with chloroform: 
methanol 2:1 (v:v) by using a modification of the method of Folch et al. (42) 
(Appendix B). The extract was washed with KCl and separated into two 
phases. The lower chloroform layer was transferred to a tube and 
evaporated to dryness under nitrogen. The lipid extract was dissolved in 
100 μl dichloromethane. TAG and PL were separated by adsorption 
chromatography on silica plates in 80:20:1 hexane: diethyl ether: acetic 
acid. The PL band was scraped from the plate and collected in a screw-cap 
tube with 1mL boron-trifluoride (BF3). The TAG band was collected in 





Fatty acids methyl esters (FAMEs) were analyzed in groups of 12 with 
one weighted standard run (Supelco 37 mixture) using the Varian 3900 
GLC and attached CP 8400 autoanalyzer. Samples were identified solely 
by a code number within a batch. FAMEs composition was determined by 
gas-liquid chromatography (GLC). Identification of FAMEs was determined 
by comparison of their relative retention times against those of pure 
standard mixtures. The relative amount of each fatty acid was quantified by 
integration of the peak at baseline and dividing the results by the total area 
for all fatty acids. Each GLC run was analyzed for quality and repeated if 
there was any indication of oxidation or underloading of the sample. 
Statistics 
Each fatty acid was expressed as a percentage of total fatty acids. 
Analysis focused on n-3 and n-6 LCPUFA, individually and combination, 
and the ratio of n-3 to n-6 LCPUFA. We evaluated specifically the 
composite group of fatty acids identified by Bougnoux et al. as related to 
the risk of breast cancer (29). The groups we used in this study were, total 
n-3 PUFA, long chain n-3 PUFA, total N-6 PUFA, and total trans fatty acids. 
The combination of total n-6 and total and long chain n-3 was the same as 
the ones used in the study of Maillard et al (34). 
Data for individual fatty acids and groups of fatty acids in each tissue 




The data were assumed to under normal distributions. Comparisons 
among tissues and lipid classes were expressed as correlation coefficients. 
Correction for DHA was made because it is our last peak during analyzing. 
We used the response factor for DHA from Supelco 37, a weighed FAME 
mixture for the correction. Pearson correlation was calculated to determine 
the relationships between fatty acids compositions in breast tissue and 
blood (both plasma and RBCs). A P value of < 0.05 was considered 



















This section includes the results for fatty acids composition of blood, 
including plasma and RBCs, and breast tissue, and the correlations 
between them. 
Sample 
Blood samples were collected from 50 women at high risk for 
developing breast cancer, and breast tissue samples were available from 
34 women. All of the samples were analyzed for fatty acid composition. The 
DHQ from 46 women at high risk of breast cancer enrolled in this study 
were collected and analyzed by a registered dietitian. 
The mean age of the subjects was 48.4 ± 9.8 years. The mean height 
and weight of the subjects were 65.0 ± 2.4 inches (19.8 ± 0.7 m) and 152.1 
± 27.8 pounds (69.0 ± 12.6 kg), respectively. The mean BMI was 25.1 ± 4.4 
kg/m2. The percentage of subjects who were premenopausal was 48% 
(n=22) and the percentage of subjects who were postmenopausal was 52% 
(n=24). A woman was defined as postmenopausal if she has not 
menstruated 12 months or more, otherwise, she was defined as 






Table 1.  Demographics of the Subjects 
Characteristic n=50 
Mean Age (y) 48.4 ± 9.8 
Height (Mean ± SD) (in) (m) 65.0 ± 2.4 (19.8 ± 0.7) 
Weight (Mean ± SD) (lb) (kg) 152.1 ± 27.8 (69.0 ± 12.6)
BMI (Mean ± SD) (kg/m2) 25.1 ± 4.4 
Premenopausal (%) 48 
Postmenopausal (%) 52 
 
Fatty Acids Compositions in Blood and Breast Tissue 
The fatty acid composition of blood samples, including plasma and RBCs, 
and breast tissues for each subject were analyzed by GLC. Each fatty acid 
was expressed as a percentage of total fatty acids. 
The mean of total n-3 PUFA of PL in plasma and RBCs for the subjects 
were 4.00 ± 1.09% and 5.47 ± 1.50%, respectively. The mean of total n-3 
PUFA of TAG in plasma was 2.21 ± 1.34%. The mean of total n-3 PUFA of 
PL and TAG in breast tissue were 0.36 ± 0.27% and 1.28 ± 0.44%, 
respectively.  
The means of total n-6 PUFA of PL in plasma and RBCs for the 
subjects were 34.04 ± 3.22% and 28.10 ± 3.45%, respectively. The mean of 




PUFA of PL and TAG in breast tissue were 2.75 ± 0.99% and 17.53 ± 
2.78%.  
The mean ratio of n-3 to n-6 PUFA in PL were 0.09 ± 0.03 and 0.12 ± 
0.03 in plasma and RBCs, respectively. The mean ratio of n-3 to n-6 PUFA 
in TAG of plasma was 0.11 ± 0.05, and the ratios were 0.20 ± 0.07 and 0.07 
± 0.03 of PL and TAG in breast tissue. The ratio of 18:3n3/18:2n6 in plasma 
and RBC PL were 0.008 ± 0.003 and 0.01± 0.003, respectively, and 0.06 ± 
0.02 in TAG of plasma. The mean ratio of 18:3n3/18:2n6 in breast tissue 
were 0.02 ± 0.01 and 0.05 ± 0.01 in PL and TAG. The mean ratio of n-3 
LCPUFA to n-6 total PUFA in plasma were 0.11 ± 0.03 and 0.03 ±0.02 in PL 
and TAG and 0.19 ± 0.07 in RBC. In the breast tissue, the mean ratio of 
long chain n-3 PUFA/n-6 PUFA were 0.08 ± 0.04 and 0.02 ± 0.02 in PL and 
TAG, respectively. 
The percentage of subjects who were taking a n-3 PUFA (either fish oil 
or flaxseed) were 33% (n=15). The mean intakes were 1.26 ± 0.6 g n-3/d 
and 9.94 ± 4.9 g n-6/d, and the ratio of n-6/n-3 intake was approximately 
9:1. 
The PL and TAG compositions of all the fatty acids in blood (plasma 
and RBCs) were shown in Table 2 and the PL and TAG composition of all 










(Mean ± SD) (%) 
Triacylglycerol (TAG)
(Mean ± SD) (%) 
Plasma RBCs Plasma 
n-3 PUFA    
18:3n3 (ALA) 0.16 ± 0.07 0.10 ± 0.04 1.18 ± 0.38 
20:5n3 (EPA) 0.70 ± 0.40 0.61 ± 0.48 0.24 ± 0.22 
22:6n3 (DHA) 3.18 ± 0.96 4.10 ± 1.16 0.42 ± 0.39 
Total n-3a 4.00 ± 1.09 5.47 ± 1.50 2.21 ± 1.34 
n-6 PUFA    
18:2n6c (LA) 20.37 ± 3.20 10.30 ± 1.40 21.19 ± 4.01 
20:4n6 (AA) 10.36 ±1.93 13.29 ± 2.07 1.55 ± 0.50 
Total n-6b 34.04 ± 3.22 28.10 ± 3.45 28.35 ± 3.97 
Monounsaturated 
FA    
18:1n9c (OA) 8.14 ± 1.25 11.21 ± 0.87 31.02 ± 3.94 
Trans FA    
Total transc 1.54 ± 0.46 1.98 ± 0.59 1.29 ± 0.62 
Ratios n-3/n-6    
18:3n3/18:2n6 0.008 ± 0.003 0.01± 0.003 0.06 ± 0.02 
Total n-3/n-6 0.09 ± 0.03 0.12 ± 0.03 0.11 ± 0.05 
LC n-3d/total n-6 0.11 ± 0.03 0.19 ± 0.07 0.03 ± 0.02 
a Included: 18:3n3, 20:3n3, 20:5n3, 22:5n3, 22:6n3.  
b Included: 18:2n6c, 20:3n6, 20:4n6, 22:4n6, 22:5n6. 
c Included: 18:1n9t, 18:2n6t. 




Table 3.  Fatty Acids Composition in Breast Tissue Samples (n=34) 
 Phospholipid (PL) 
(Mean ± SD) (%) 
Triacylglycerol (TAG)
(Mean ± SD) (%) 
n-3 PUFA   
18:3n3 (ALA) 0.03 ± 0.04 0.86 ± 0.21 
20:5n3 (EPA) 0.05 ± 0.05 0.14 ± 0.34 
22:6n3 (DHA) 0.24 ± 0.29 0.10 ± 0.08 
Total n-3a 0.36 ± 0.27 1.28 ± 0.44 
n-6 PUFA   
18:2n6c (LA) 2.06 ± 2.46 16.66 ± 2.70 
20:4n6 (AA) 1.10 ±1.63 0.38 ± 0.19 
Total n-6b 2.75 ± 0.99 17.53 ± 2.78 
Monounsaturated FA   
18:1n9c (OA) 12.76 ± 2.07 35.95 ± 3.23 
Trans FA   
Total transc 6.72 ± 1.21 2.32 ± 0.68 
Ratios n-3/n-6   
18:3n3/18:2n6 0.02 ± 0.01 0.05 ± 0.01 
Total n-3/n-6 0.20 ± 0.07 0.07 ± 0.03 
LC n-3d/ total n-6 0.08 ± 0.04 0.02 ± 0.02 
a Included: 18:3n3, 20:3n3, 20:5n3, 22:5n3, 22:6n3.  
b Included: 18:2n6c, 20:3n6, 20:4n6, 22:4n6, 22:5n6. 
c Included: 18:1n9t, 18:2n6t. 











Correlations between Blood and Breast Tissue Fatty Acids 
Composition 
The relationship between total n-3 PUFA composition in blood (plasma 
and RBCs) and breast tissue were shown in Table 4. No significant 
correlation was found in the total n-3 fatty acids profile between blood and 
the fine needle aspirates of breast tissue. 
The correlations of n-6 PUFA profile were shown in Table 5. The 
plasma total n-6 PUFA composition in TAG was significantly correlated with 
the total n-6 PUFA composition of breast tissue in both PL and TAG 
(p<0.01). However, no significant correlation was found between the PL in 
RBCs or plasma and the lipid profile in breast tissue. 
The results of the correlation of the n-3 PUFA to n-6 PUFA ratio 
between blood species and tissue were shown in Table 6. No significant 
correlation was found between the ratio of 18:3n3/18:2n6 in the breast 
tissue and the blood. There was a significant correlation between the ratio 
of n-3 PUFA to n-6 PUFA in PL of breast tissue and that in the PL of both 
RBCs and plasma (p<0.01), and TAG of plasma (p<0.01). 
The relationship of the ratio of n-3 LCPUFA to n-6 PUFA between 
blood (plasma and RBCs) and breast tissue was shown in Table 7. No 
significant correlation was found between the n-3 LCPUFA to n-6 PUFA 




plasma (p<0.01). The ratio of n-3 LCPUFA to n-6 PUFA in the PL of breast 
tissue was significantly correlated with that in the PL of RBC (p<0.01) and 
plasma (p<0.01), respectively. 
 
Table 4.  Correlations of Total N-3 PUFA Composition between Blood 
(plasma and RBCs) and Breast Tissue 
 
Lipid Profile of Fine Needle Aspirates 
PL TAG 
r P value r P value 
RBC PL 0.102 0.612 0.012 0.949 
Plasma PL -0.001 0.996 0.169 0.355 
TAG 0.016 0.936 0.042 0.821 
* Correlation is significant at the 0.05 level (2-tailed) 




















Table 5.  Correlations of Total N-6 PUFA Composition between Blood 
(plasma and RBCs) and Breast Tissue 
 
Lipid Profile of Fine Needle Aspirates 
PL TAG 
r P value r P value 
RBC PL 0.046 0.832 -0.088 0.631 
Plasma PL 0.200 0.350 0.027 0.884 
TAG 0.521** 0.009 0.533** 0.002 
* Correlation is significant at the 0.05 level (2-tailed) 




























Table 6.  Correlations of N-3/N-6 PUFA Composition between Blood 
(plasma and RBCs) and Breast Tissue 
 
 
Lipid Profile of Fine Needle 
Aspirates 
 PL TAG 





RBC PL 0.096 0.634 0.209 0.259 
Plasma PL -0.047 0.818 0.126 0.498 
 TAG 0.191 0.340 0.083 0.657 
Total n-3/n-6 
RBC PL 0.801** 0.000 0.201 0.270 
Plasma PL 0.653** 0.000 0.025 0.893 
TAG 0.627** 0.000 -0.079 0.666 
* Correlation is significant at the 0.05 level (2-tailed) 


















Table 7.  Correlations of N-3 LCPUFA/N-6 PUFA Composition 
between Blood (plasma and RBCs) and Breast Tissue 
 
Lipid Profile of Fine Needle Aspirates 
PL TAG 
r P value r P value 
RBC PL 0.631** 0.000 0.276 0.133 
Plasma PL 0.524** 0.003 0.501** 0.004 
TAG 0.313 0.092 0.272 0.138 
* Correlation is significant at the 0.05 level (2-tailed) 


















The purpose of this study was to examine the fatty acids composition 
in breast tissue of women at increased risk of breast cancer and whether 
the fatty acids composition in blood relate to that in the breast tissue in 
women at increased risk of breast cancer.  
Fatty Acids Composition in Blood and Breast Tissue in Women at 
High Risk of Breast Cancer 
Maillard et al. (34) reported fatty acids composition of breast adipose 
tissue in 88 women had benign breast disease. The mean percentage of 
total n-3 PUFA in their participants was 0.98 (SE=0.027), and the mean 
percentage of total n-6 PUFA was 14.67 (SE=0.420). The average ratio of 
18:3n3/18:2n6 and long chain n-3/n-6 PUFA were 0.039 (SE=0.001) and 
0.034 (SE=0.002), respectively. The combination of both total n-3 and n-6 
PUFA Maillard et al. (34) used in their research were the same as those in 
the current study. Mean percentage of total n-3 and n-6 PUFA composition 
in TAG of breast tissue was higher than mean percentages of total n-3 and 
n-6 PUFA in previous study by Maillard et al (34). The ratio of n-3 
LCPUFA/n-6 PUFA was lower than the previous study (34).  
Takata et al. (43) reported the fatty acids composition in plasma 




percentage of total n-3 PUFA and n-6 PUFA in those participants were 3.80 
and 33.8, respectively. Both of them were lower than the results in the 
current study. The ratio of total n-3 to n-6 PUFA in Takata et al. study was 
0.11, which was higher than the result in the present study. The 
combination used for total n-3 and n-6 PUFA in report of Takata et al. were 
the same as those in the current study as well.  
Both Maillard et al. (34) and Takata et al. (43) subjects were women 
with breast cancer. The population in our current study was women with 
high risk for subsequent development of breast cancer but not yet 
diagnosed with breast cancer. The difference between the characteristics 
of subjects may cause these variations in those fatty acids compositions. 
Also, different supplement used may affect the fatty acids composition in 
the blood and breast tissue. 
The compositions of fatty acids in PL and TAG were quite different, 
regardless of the blood or breast tissue. The mean percentage of oleic 
acids in the TAG was much higher than that in the PL in both plasma and 
breast tissue. This result is consistent with the composition of fatty acid in 
human milk, which suggests that this fatty acid can be assimilated by the 
breast tissue itself. The mean percentage of arachidonic acid (AA) was 
lower in the TAG than in the PL, especially in the plasma. The fatty acid 




profile, the DHA and EPA much higher in the PL of plasma and RBC than 
those in the breast tissue, and so did the AA. The major fatty acids of PL in 
the breast tissue were palmitic acid, stearic acid and oleic acid. 
No previous study was found that examined the fatty acid composition 
in RBC phospholipid or the comparison of the fatty acids composition in 
both PL and TAG in blood and those in breast tissue using a population 
with high risk of breast cancer. 
Correlation of Fatty Acids Composition in Blood and Breast Tissue 
A correlation was found between the ratio of n-3/n-6 PUFA in blood 
samples and breast tissue in women at high risk of breast cancer. Total 
n-3/n-6 PUFA in PL in plasma and RBC were significantly correlated to in 
fine needle aspirates. The ratio of long chain n-3 to total n-6 PUFA in PL in 
plasma and RBC was found related to that in breast tissue, and the ratio of 
n-3 LCPUFA/ n-6 PUFA in PL in plasma was significantly correlated to that 
in TAG in breast tissue, suggesting the ratio of n-3/n-6 PUFA may be a 
good indicator of the fatty acids composition in breast tissue. However, the 
combination of n-3 PUFA and n-6 PUFA was not found related to those in 
breast tissue independently, indicating that a combination of n-3 and n-6 






There were several studies did lipids of breast tissue and risk of breast 
cancer. A study conducted in France found that the lipidome of breast 
adipose tissue may predict the risk of breast cancer. The investigators 
found the level of DHA, and the ratio 18:3n3/18:2n6 and long chain n-3/ 
total n-6 PUFA were inversely associated with breast cancer incidence (34). 
The European Community Multicenter Study on Antioxidants, Myocardial 
Infarction, and Cancer (EURAMIC) breast cancer study made a similar 
observation (44). Another study in North America also found the same 
results for long chain n-3 PUFA (45). All of the studies concluded that the 
ratio of total n-3 to n-6 PUFA in breast tissue predict the risk of breast 
cancer. However, other studies based on a similar design were not 
conclusive (38, 39). 
In the current study, no relationship was found between independent or 
total n-3 and n-6 PUFA in the blood (both plasma and RBC) and the breast 
tissue in women at high risk of breast cancer. For n-3 and n-6 PUFA, no 
correlation was found in the ratio of 18:3n3 to 18:2n6 in the blood and the 
breast tissue, but there were significant correlation between total and long 
chain n-3 PUFA to total n-6 PUFA in PL of both plasma and RBC and PL in 
fine needle aspirates, suggesting that the ratio of total or long chain n-3 
PUFA to total n-6 PUFA may be a biomarker of changing of fatty acids 




breast cancer. This may allow the population of a high risk of breast cancer 
to prevent breast cancer with a dietary change. 
A significant correlation was found in the ratio of total n-3 to n-6 PUFA 
in PL between RBC and breast tissue (figure 1). This result suggests that 
the ratio of total n-3/n-6 PUFA in the PL of RBC may be a convincing 
biomarker of that ratio in breast tissue. A high ratio of total n-3/n-6 PUFA 
may reflect a high ratio in the breast tissue. A weak correlation was found 
the in ratio of long chain n-3 to total n-6 PUFA in the PL of plasma and that 
in the TAG of breast tissue (figure 2), but the correlation was not as strong 
as those found in PL of RBC and breast tissue. Although results in plasma 
PL were highly correlated with those in plasma TAG, no relationship was 
found in fatty acid composition between PL and TAG in breast tissue. 
Cognault et al. (46) found that the action of n-3 PUFA on mammary 
tumorigenesis depended on their interaction with other components of 
lipids in a rat model. Bougnoux et al. (28) found fatty acids were not 
independent variables. These results may explain the reason the 
independent n-3 and n-6 PUFA in blood do not correlated with those in 
breast tissue but the ratio did. These results indicated that focusing on 
single lipid component may not be appropriated approach because of the 
complex interactions between all the fatty acids that determine the lipid 




No previous studies assessed the correlation of fatty acids 
composition between the blood (plasma and RBC) and breast tissue as a 
biomarker. All of the previous studies focus on fatty acids composition and 
breast cancer risk were based on breast tissue fatty acids levels. 
 
 
Figure 1. Correlation in the Ratio of Total n-3/n-6 PUFA in PL between 





Figure 2. Correlation in the Ratio of LC n-3/total n-6 PUFA between 
Plasma PL and Breast Tissue TAG 
 
Limitations 
    The limitations for this study were the sample size and control of 
confounding factors that influenced the fatty acids composition in blood and 
breast tissue. 
Because the study was done in women at high risk for breast cancer, 
the women studied were also at high risk of breast cancer. We did not have 
any basis to estimate study power. A power analysis was not conducted to 
determine a specific sample size required to obtain statistical significance 




n-3 LCPUFA can be found with a sample of 10. The sample size for this 
study was 50. We chose this size because this sample size was able to 
explore different individual and combinations of fatty acids and to compare 
women who consume n-3 LCPUFA supplements to those who do not – this 
was occurring with 33% frequency in the cohort. However, the number of 
women enrolled in this study compared less than other reports in the 
literature related to fatty acids composition and breast cancer. The previous 
studies conducted by Maillard et al. (34) and Takata et al. (43) had 88 and 
130 subjects, respectively. A larger sample will be needed in the future 
which will allow us to examine potentially influential variables such as 
menopausal status, BMI, and total fat intake.  
Another limitation of this study was the influence factors. Only one 
blood sample was obtained from the study participants. One blood sample 
may not reflect the true fatty acids composition of the blood. Blood sample, 
especially the plasma, influenced by many outside factors, such as 
changes of diet, taking or stopping supplements, and et al. Supplements of 
n-3 PUFA will affect coagulation, participants were required to stop all 
supplements three weeks before the biopsy. This change in some 
participants may affect the blood fatty acids composition. Two or more 






In the current study, the ratio of total or long chain n-3 PUFA to total n-6 
PUFA in blood was significantly correlated with those in breast tissue. 
Although other n-3 or n-6 PUFA combination in blood did not correlate with 
those in breast tissue, the results suggest the possibility of using fatty acids 
composition in blood as a biomarker to indicate the changing of fatty acids 
composition in breast tissue, which may be used in future interventions. 
This biomarker will be useful to reflect the fatty acids profile in breast tissue 
while avoiding the surgery for obtaining breast biopsies which are time 
consuming and may be painful or lead to bleeding or bruising. 
Future Studies 
For the current study, only 50 women were examined for the fatty acids 
composition relationship between blood and breast tissue, and only 34 
breast tissue samples were obtained. A larger sample size will be needed 
to confirm the results in this study. Adjustment of individual characters, 
such as BMI, diet fat intake and supplement intake, are also needed in 
future studies for controlling the confounding factors. It would be beneficial 
for future researchers to try other combination of fatty acids in blood and 






In this study, significant correlations were found between the ratio of 
total and long chain n-3 PUFA to total n-6 PUFA in blood and breast tissue. 
However, no significant correlations were found between total n-3 PUFA 
and total n-6 PUFA in blood and breast tissue with the population having a 
high risk of breast cancer. The results in the study suggested that there 
may be a relationship between the fatty acids composition in blood and 
breast tissue. 
In conclusion, the ratio of total or long chain n-3 PUFA to total n-6 
PUFA might be a good biomarker of fatty acids composition in breast tissue 
to predict breast cancer risk. However, these results are need further 
validated in the future. Future larger studies are also need to determine 














The purpose of this study was to determine the fatty acids composition 
in breast tissue in women with increased risk of breast cancer and if the 
fatty acid composition in both PL and TAG in blood (both plasma and RBC) 
correlated to the fatty acid composition in breast tissue. 
Fifty patients were enrolled in a larger study to develop an assessment 
of breast cancer risk based on epidemiologic and biologic risk variables at 
University of Kansas Medical Center. Blood and tissue samples were taken 
and DHQ (including usual supplement intake) were distributed when the 
subject were enrolled. Blood and breast tissue samples were analyzed by 
GLC and calculated by their area percentage. 
The total n-3 and n-6 PUFA composition in TAG of breast tissue and 
blood were higher than mean percentages of total n-3 and n-6 PUFA in 
previous study by Maillard et al. (34) and Takata et al (43). The ratio of n-3 
LCPUFA/n-6 PUFA in breast tissue and blood were lower than the previous 
studies (34, 43) when using a same combination of the fatty acids. 
A correlation was found between the ratio of n-3/n-6 PUFA in blood 
samples and breast tissue in women at high risk of breast cancer. Total 
n-3/n-6 PUFA in PL in plasma and RBC was significantly correlated to that 




PUFA in PL in plasma and RBC was found related to that in breast tissue as 
well (p<0.01), and the ratio of n-3 LCPUFA/ n-6 PUFA in PL in plasma was 
also significantly correlated to that in TAG in breast tissue (p<0.01), 
suggesting that the ratio of n-3/n-6 PUFA may be a good indicator of the 
fatty acids composition in breast tissue.  
    Therefore, the ratio of total or long chain n-3 PUFA to total n-6 PUFA 
might related to fatty acids composition in breast tissue and the results 
suggested the possibility of using fatty acids composition in blood as a 
biomarker to indicate the breast cancer risk. Further studies are still needed 
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1. FNA samples are collected into 250 µl sterile phosphate-buffered saline 
(PBS) in sterile 2 ml pp cryo-vials in the clinic.  Two vials are collected 
for each breast.  The first 2 sticks from the upper outer quadrant of 
one breast are collected into 1 vial (the PBS is used to rinse the FNA 
sample from the syringe needle) and immediately snap-frozen in liquid 
nitrogen.  The first stick from the upper inner quadrant is collected into 
a second vial and snap-frozen.  The procedure is repeated for the 
other breast into 2 additional vials.  The first 1 or 2 sticks from each 
quadrant are usually not bloody; excessively bloody sticks are not 
included in the frozen FNA samples. 
2. After all samples have been frozen in liquid nitrogen they are 
transferred to -80°C and transported (with -80°C frozen cold-packs) 
from the clinic to the research laboratory where they are stored at 
-80°C.  At approximately 2 week intervals Teresa Phillips logs-in 
samples from the clinic and places the frozen FNA samples in labeled 
storage boxes at -80°C. 
3. Frozen FNA samples from ~10 patients can be handled at one time for 
thawing, pooling, and aliquotting.  Before removing samples from 
freezer prepare for each patient:   
a) label 1 sterile pp 12 x 75 mm snap-cap tube for pooling sample, 




b) label and prepare 1 sterile nuclease-free 1.5 ml tube for RNA 
extraction sample by adding 750 µl TRIzol® LS to tube and leave at 
room temperature  
c) label 1 sterile 1.5 ml tube for sample for cytokine analysis, place on 
ice  
d) label 1 sterile 1.5 ml tube for sample to be transferred to Dr. 
Carlson’s lab for fatty acid analysis, place on ice 
e) label 1 sterile 1.5 ml tube for sample to be used for total protein 
assay (for “normalization”), place on ice 
4. Remove frozen FNA samples from -80°C to ice.  Working one patient 
at a time, thaw frozen tissue samples in cold water bath (cold tap water) 
until just thawed, then put vials on ice and keep on ice throughout 
procedure.    
5. Using 1000 µl pipettor, mix contents of each vial and transfer to 12 x 75 
mm sterile pp snap-cap tube, on ice.  Measure and record total 
volume.  Mix well by pipetting a few times. 
a) Remove 250 µl and add to 750 µl TRIzol® LS, mixing well by 
pipetting.  Leave at room temperature at least 5 min (longer is OK) 
then after all samples collected store at -80°C until ready to isolate 




b) Remove 250 µl and transfer to sterile 1.5 ml tube for cytokine 
analysis (place tube into pulverized dry ice), store at -80°C.   
6. Use Fisher 100 Sonic Dismembrator to lyse main sample, 3X setting 5 
(≤15 W) 10-15 sec each, keeping sample tube submerged in ice. 
7. Transfer 250 µl of sonicated sample to sterile 1.5 ml tube (place tube 
into pulverized dry ice), store at -80°C before transport to Dr. Carlson’s 
lab for extraction and analysis. 
8. Transfer remainder of sonicate to tube labeled for total protein assay 
sample (place tube into pulverized dry ice); after all samples collected 








































Spinning Blood:  RBC and Plasma 
1. Before samples can be centrifuged, they must be balanced. To 
balance you will need an even number of tubes and they must have 
equal amounts of either sample or water. There are empty 4ml tubes 
to fill with water on the shelf to the left of the centrifuge. 
2. Remove the caps and place in opposite buckets in centrifuge. Turn 
centrifuge on (switch is on the right side). Set the centrifuge to spin 
at 3000*g for 10 minutes at 4°C.   
3. While blood is being spun, log the samples in KUDOS log book and 
set out three Pasteur pipettes with bulbs, and two 2 ml 
microcentrifuge tubes for each sample.   
4. Each tube must be labeled with RBC/Plasma, subject ID, subject 
initials, baseline/ cord blood /postpartum/4 month, date, and initials 
of who spun the blood. 
5. When samples are ready, transfer the top (yellow) layer of plasma to 
the tube labeled plasma with a Pasteur pipette. 
6. After the plasma layer is removed, there is a thin white layer above 
the RBCs that needs to be removed. This layer may be discarded 




7. Last, using a clean Pasteur pipette transfer the remaining RBCs to 
the RBC labeled tube.   
8. Layer each tube with Nitrogen and place in appropriate box in -80 
freezer. The third shelf contains the tray for the KUDOS study. 
9. Discard dirty pipettes in biohazard box on counter. Any 
contaminated gloves, bulbs, and bags must be thrown away in the 
biohazard waste. 
Extraction: 
Before starting the extraction: turn on the N-evaporator water bath, cut TLC 
plates into 4 plates and place in TempCon Oven, turn on TempCon Oven. 
Set out 2 test tube racks and eighteen 15 mL tubes with caps. New tubes 
are required for the methylation step. Number tubes 1-6 so that there are 3 
sets. Also, set up TLC chamber with 80:20:1 Hexane: Ether: Acetic acid.  
Place a sheet of filter in tank. Chambers last for about 2 days or about 12 
samples.   
In the first set of 15mL test tubes: 
1. Pipette 4mL of methanol into clean extraction tubes. 
2. Add 500μL RBC or Plasma, cap, and immediately vortex for a few 
seconds. 
3. Add 100μL internal standard (17:0) and vortex.  The 17:0 PE 




4. Add 8mL Chloroform and vortex.  Use the multi-tube vortexer on 
the lab counter. 15 minutes for RBC and 10 minutes for Plasma. 
5. Transfer contents through a funnel lined with filter paper (Whatman 
#1) into a clean extraction tube. 
6. Add 1.6mL (0.5 Molarity) KCl and vortex for 10 seconds. 
7. Centrifuge for 5 minutes at 750 r.p.m. and then using a clean 
Pasteur pipette discard upper phase into appropriate hazardous 
waste bottle. 
8. Evaporate the lower phase in a water bath at 35°C under nitrogen. 
This takes about 30-45 minutes. [Add 1-2mL benzene and 
re-evaporate if small amounts of water remain].  
*While waiting for samples to evaporate, pipette 1mL BF3 into 3rd set 
of extraction tubes and place on ice. Turn on dry bath. 
Separation of total phospholipids: 
9. When extract is completely dry, dissolve in 100μL dichloromethane 
and place immediately on ice until ready to spot plates.   
10. When plates have been heated for at least 20 minutes, take out of 
oven and allow to cool.  Then spot all 100μL of a sample on the 
plate and place immediately in the TLC chamber with 80:20:1 





11. Allow the solvent front to run to the top of the plate and then remove 
from TLC chamber to dry.  
12. Identify phospholipid line (it is the same line as the spotting line). 
Remove the gel containing the lipid fraction of interest with a single 
edge razor blade onto weighing paper.  Carefully transfer the gel to 
the 3rd set of extraction tubes containing 1 ml cold BF3.  
Separation of triacylglycerol: 
13. When extract is completely dry, dissolve in 100μL dichloromethane 
and place immediately on ice until ready to spot plates.   
14. When plates have been heated for at least 20 minutes, take out of 
oven and allow to cool. Then spot all 100μL of a sample on the plate 
and place immediately in the TLC chamber with 80:20:1 Hexane: 
Ether: Acetic Acid. (Two spotted plates fit in the chamber at a time). 
15. Allow the solvent front to run to the top of the plate and then remove 
from TLC chamber to dry. Spray BBOT on the plate 
Identify triacylglycerol line under UV reader (it is the middle band on 
the plate). Remove the gel containing the lipid fraction of interest 
with a single edge razor blade onto weighing paper.  Carefully 
transfer the gel to the 3rd set of extraction tubes containing 0.25ml 






16. Layer each tube with Nitrogen and place on ice until all samples are 
finished spotting. 
17. Tighten caps and place in dry bath at 100°C for 10 minutes. 
18. After 1-2 min. retighten caps as they tend to loosen during heating. 
19. After transmethylation is complete, immediately place tubes on ice.  
When tubes are very cool, open and add 1ml of H2O and 2 mL 
pentane. 
20. Vortex for 1-2 minutes to extract fatty acid methyl esters (FAME) into 
the pentane phase, then centrifuge for 5 min. at 800 r.p.m. 
21. Transfer the upper phase (pentane) with a Pasteur pipette to a 
Varian 2mL vial. Transmethylation tubes may be thrown away in the 
glass container when done. 
22. Concentrate the FAME under a stream of Nitrogen. 
23. When completely dry, add 70μL of dichloromethane to vial. Swirl 
tube to catch FAME on all sides and then transfer with Hamilton 
syringe to sleeve. Place sleeve inside of 2 mL vial and cap with 
Teflon-lined cap. 
24. Place sample in autosampler tray to inject or in freezer until it can be 
analyzed.  
 
